Global /China /Healthcare /Drug Manufacturers - General /688373

Shanghai MicuRx Pharmaceutical Co., Ltd.

688373

• SSE: 688373 • Delayed

5.97CNY 1.5%

0.8822 USD

As of 14 June 2026, Shanghai MicuRx Pharmaceutical Co., Ltd. has a market cap of $578.17M USD, ranking #14167 globally and #4365 in China. It ranks #1262 in the Healthcare sector, and #469 in the Drug Manufacturers - General industry.

Global Rank

14167

Country Rank

4365

Sector Rank

1262

Industry Rank

469

Key Stats

Market Cap

$578.17MUSD

3.92B CNY

Enterprise Value

$571.53MUSD

3.87B CNY

Revenue (TTM)

$22.23MUSD

150.62M CNY

EBITDA (TTM)

-$29.97MUSD

-202.84M CNY

Net Income (TTM)

-$29.73MUSD

-201.43M CNY

EBITDA Margin

-135%

Profit Margin

-134%

PS Ratio

26.0

PB Ratio

21.5

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Yuan Zhengyu open_in_new

Employees

166

Founded

2007

Website

micurxchina.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
1.5%	-2.8%	-4.2%	-7.7%	-24%	-2.6%	-2.8%	-41%	-65%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	688373 上海盟科药业股份有限公司 Class A ISIN: CNE100005PX4 Shares Out.: Shares Outstanding: 605.638M¹ Shares Float: 605.586M² TV: TradingView: SSE: 688373 SA: Stock Analysis: SHA: 688373 YF: Yahoo Finance: 688373.SS GF: Google Finance: SHA: 688373 BA: Barron's: 688373 MS: Morningstar: XSHG: 688373	5.97 CNY	TV: TradingView: SSE: 688373 SA: Stock Analysis: SHA: 688373 YF: Yahoo Finance: 688373.SS GF: Google Finance: SHA: 688373 BA: Barron's: 688373 MS: Morningstar: XSHG: 688373

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Shanghai MicuRx Pharmaceutical Co., Ltd.

Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. The company was founded in 2007 and is based in Shanghai, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.85B 364.89B CNY 9K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.64B 336.36B CNY 8K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.52B 223.48B HKD 5K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 3K%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.51B 111.89B CNY 3K%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 3K%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 132K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 95K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 62K%	97.4	United States
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 56K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 50K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 47K%	20.5	Switzerland

chevron_leftBack